Belin A, Grieu P, Mabire J P, Kleszcz A, Sesboué B, Breut C, Scanu P, Albessard F, Grollier G, Potier J C
Centre de réadaptation cardiaque de Trouville-sur-Mer.
Arch Mal Coeur Vaiss. 1990 Mar;83(3):393-8.
Calcium channel blockers are now recommended for the treatment of stable angina but few studies have been carried out comparing the efficacy of verapamil and diltiazem in this indication. The short-term efficacy of these two drugs was compared in a double-blind crossover trial in 12 patients. The following protocol was used, 24 hour selection period followed by two crossover treatment periods versus double placebo. Exercise stress tests were performed 2 hours after the last dose at the end of each treatment period. Each patient underwent 3 stress tests: the first during the selection period whilst taking verapamil and diltiazem placebo (ET0), the second after the first treatment period at day 7 (ET1) and the third after the second treatment period at day 14 (ET2). A comparison of exercise capacity (ET0 to ET1 and ET2) showed improved effort tolerance and an increase in the ischaemic threshold with calcium blocker therapy. The duration of effort, the maximum sustained load, the rate-pressure product and the time to ST depression were all significantly increased. On the other hand, there were no significant changes in the percentage theoretical maximum heart rate attained, the heart rate at which ST depression occurred, the maximum ST depression and the incidence of angina. A comparison between ET1 and ET2 did not show any difference in the parameters of maximum effort or of the appearance of myocardial ischaemia. The comparison of exercise stress tests performed after treatment with verapamil and after diltiazem showed that the total duration of exercise, the maximum sustained load (in watts) and the rate-pressure product were identical.(ABSTRACT TRUNCATED AT 250 WORDS)
钙通道阻滞剂目前被推荐用于治疗稳定型心绞痛,但针对维拉帕米和地尔硫䓬在该适应症上疗效比较的研究较少。在一项针对12例患者的双盲交叉试验中比较了这两种药物的短期疗效。采用以下方案:24小时筛选期,随后是两个交叉治疗期与双安慰剂对照。在每个治疗期结束时,于最后一剂药物服用2小时后进行运动应激试验。每位患者接受3次应激试验:第一次在筛选期服用维拉帕米和地尔硫䓬安慰剂时进行(ET0),第二次在第7天的第一个治疗期后进行(ET1),第三次在第14天的第二个治疗期后进行(ET2)。运动能力(ET0至ET1和ET2)的比较显示,钙通道阻滞剂治疗可改善运动耐力并提高缺血阈值。运动持续时间、最大持续负荷、心率血压乘积和ST段压低时间均显著增加。另一方面,达到的理论最大心率百分比、ST段压低时的心率、最大ST段压低和心绞痛发生率均无显著变化。ET1和ET2之间在最大运动参数或心肌缺血表现方面未显示出任何差异。维拉帕米治疗后与地尔硫䓬治疗后进行的运动应激试验比较显示,运动总持续时间、最大持续负荷(以瓦特为单位)和心率血压乘积相同。(摘要截选至250字)